The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients

[1]  S. Reuter,et al.  Commentary: The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients , 2021, Frontiers in Pharmacology.

[2]  J. Sieńko,et al.  The effect of genetic variations for interleukin-10 (IL-10) on the efficacy of immunosuppressive therapy in patients after kidney transplantation. , 2020, International immunopharmacology.

[3]  J. Buendía,et al.  Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation , 2020, Pharmaceutics.

[4]  G. Patrinos,et al.  CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients , 2020, Frontiers in Pharmacology.

[5]  V. Haufroid,et al.  Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives , 2020, Expert opinion on drug metabolism & toxicology.

[6]  Jing Ling,et al.  Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation , 2020, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  D. DuBay,et al.  A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  K. Kaku,et al.  Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients , 2020, International journal of molecular sciences.

[9]  N. Harada,et al.  Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation , 2020, International journal of molecular sciences.

[10]  S. Masuda,et al.  Significance of ethnic factors in immunosuppressive therapy management after organ transplantation. , 2020, Therapeutic drug monitoring.

[11]  C. Ponticelli,et al.  Treatment of dyslipidemia in kidney transplantation , 2020, Expert opinion on drug safety.

[12]  U. Maggiore,et al.  Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. , 2020, Transplantation reviews.

[13]  A. Abid,et al.  CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis , 2020, The Pharmacogenomics Journal.

[14]  W. Guan,et al.  Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  G. Wong,et al.  Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink? , 2019, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  V. Kutala,et al.  Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases , 2019, Pharmacological reports : PR.

[17]  Zi-jie Wang,et al.  Association of genetic variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with tacrolimus pharmacokinetics in renal transplant recipients. , 2019, Current drug metabolism.

[18]  K. Akashi,et al.  Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation , 2019, International journal of molecular sciences.

[19]  L. Rostaing,et al.  An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization , 2019, Expert opinion on drug safety.

[20]  Baochi Ou,et al.  TLR9 rs352139 Genetic Variant Promotes Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Posttransplantation Period , 2019, Pharmacotherapy.

[21]  D. Mager,et al.  Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? , 2018, Journal of clinical pharmacology.

[22]  U. Christians,et al.  Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report , 2019, Therapeutic drug monitoring.

[23]  R. Deng,et al.  Association of CYP3A5, CYP2C8, and ABCB1 Polymorphisms With Early Renal Injury in Chinese Liver Transplant Recipients Receiving Tacrolimus. , 2018, Transplantation proceedings.

[24]  F. Lemaitre,et al.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation , 2018, Clinical Pharmacokinetics.

[25]  D. Kuypers,et al.  Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers , 2018, Drug Metabolism and Disposition.

[26]  D. Mager,et al.  Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients , 2018, Journal of clinical pharmacology.

[27]  A. Somogyi,et al.  CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose‐adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post‐Kidney Transplantation , 2018, Basic & clinical pharmacology & toxicology.

[28]  Zhihai Peng,et al.  Association of donor small ubiquitin‐like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[29]  B. Suwelack,et al.  Tacrolimus - Pharmacokinetic Considerations for Clinicians. , 2018, Current drug metabolism.

[30]  W. Guan,et al.  Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. , 2018, Pharmacogenomics.

[31]  M. Matsumoto,et al.  Polymorphism of IL‐10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib , 2017, Hematological oncology.

[32]  M. Hirata,et al.  Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium–Based Treatment in Brazilian Kidney Transplant Recipients , 2017, Pharmacotherapy.

[33]  L. Ye,et al.  Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients , 2017, Disease markers.

[34]  Haiyan He,et al.  IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients , 2017, Acta Pharmacologica Sinica.

[35]  Hsi-Chin Wu,et al.  The Role of IL-10 Promoter Polymorphisms in Renal Cell Carcinoma. , 2016, Anticancer research.

[36]  Jinghong Zhao,et al.  Lack of Association between Interleukin-10 Gene Polymorphisms and Graft Rejection Risk in Kidney Transplantation Recipients: A Meta-Analysis , 2015, PloS one.

[37]  M. Loriot,et al.  Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  É. Jacqz-Aigrain,et al.  Choosing the right dose of tacrolimus , 2014, Archives of Disease in Childhood.

[39]  F. Gao,et al.  Association of TNF‐α, TGF‐β1, IL‐10, IL‐6, and IFN‐γ gene polymorphism with acute rejection and infection in lung transplant recipients , 2014, Clinical transplantation.

[40]  Ze-yan Zhong,et al.  Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients , 2014, PloS one.

[41]  D. Hesselink,et al.  The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation , 2014, Clinical Pharmacokinetics.

[42]  C. Polidori,et al.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. , 2013, World journal of gastroenterology.

[43]  S. Aliño,et al.  Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation , 2013, Pharmacogenetics and genomics.

[44]  V. Haufroid,et al.  Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. , 2011, Pharmacogenomics.

[45]  Zhihai Peng,et al.  Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period , 2011, European Journal of Clinical Pharmacology.

[46]  Ammarin Thakkinstian,et al.  Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-analysis of individual patient data. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  D. Kuypers,et al.  Pharmacogenetics in solid organ transplantation: current status and future directions. , 2008, Transplantation reviews.

[48]  Dan Li,et al.  Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL‐10 polymorphisms in adult liver transplant patients , 2007, Journal of clinical pharmacy and therapeutics.

[49]  Guo-liang Zhang,et al.  Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[50]  H. Strobel,et al.  Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. , 2007, Archives of biochemistry and biophysics.

[51]  K. Iwasaki.  Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. , 2007, Drug metabolism and pharmacokinetics.

[52]  N. Lee,et al.  IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course During Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation , 2005, Transplantation.

[53]  Jung Lim Lee,et al.  IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course during Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation. , 2004 .

[54]  J. Gorski,et al.  In vivo effects of interleukin‐10 on human cytochrome P450 activity , 2000, Clinical pharmacology and therapeutics.

[55]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.